We want your views
Wednesday 4 May 2022
We've been asked by the National Institute for Health and Care Excellence (NICE) to help them to assess a treatment called Regorafenib, also known as Stivarga. This medicine is for the treatment of people with advanced bowel cancer, who have previously received treatment. NICE has contacted us because we support and work with people who have been affected by bowel cancer.
NICE's role is to approve newly licensed medicines that represent good value for money for the NHS in England and Wales. NICE looks at information supplied by the manufacturer of the medicine on whether they believe there are clear health benefits of the medicine, and justification of the price being charged. As the NHS has limited resources, NICE wants to make sure that medicines which represent good value for money are available for use as quickly as possible so that they can benefit patients.
As well as studying the scientific evidence, NICE will also take into account the views and experiences of patients with bowel cancer and their families and carers. And this is where you can help the decision making of NICE.
To share your views, please take our survey. This survey is for anyone who has been treated for advanced bowel cancer and their families and carers.
The survey has nine questions and will take up to 10 minutes to complete. You can answer all the questions or skip any that you can't or don't wish to answer. Your responses will be shared with NICE to help them make a decision.
The survey closes on Monday 16 May at 10am.
